Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.
Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings from a population-based study, which showed that many patients believe they had no choice about whether or not to receive radioactive iodine, even though it often does not improve survival. There is a need, she says, for better shared decision-making (Abstract 159).
Simron Singh, MD, MPH, of Sunnybrook Health Sciences Centre, discusses initial results of his data on a new patient experience measurement strategy used at Cancer Care Ontario.
Jeremy Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses the ways in which patient navigators affect cancer care and how patients benefit.
Jay B. Shah, MD, of Stanford University, discusses the role that surgeons can play as gatekeepers to the opioid epidemic, including the view that complex cancer operations can be performed with little to no opioid use (Abstract 269).
Monika K. Krzyzanowska, MD, MPH, of Princess Margaret Cancer Centre, summarized the Keynote Lecture, including the points that clinicians should carefully plan their quality improvement projects, understand the barriers to quality, and ensure their efforts are sustainable.
